Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals (JAZZ) Stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction on Friday, April 13th. The shares were sold at an average price of $157.49, for a total transaction of $31,498.00. Following the completion of the sale, the executive vice president now directly owns 27,481 shares in the company, valued at $4,327,982.69. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michael Patrick Miller also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Wednesday, March 14th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $151.12, for a total transaction of $30,224.00.
  • On Wednesday, February 14th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $139.99, for a total transaction of $27,998.00.

JAZZ opened at $156.07 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.15 and a current ratio of 3.29. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $163.75. The firm has a market cap of $9,333.52, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 0.82 and a beta of 0.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.73 by ($0.15). Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. The business had revenue of $436.40 million for the quarter, compared to analyst estimates of $440.91 million. equities research analysts anticipate that Jazz Pharmaceuticals will post 11.48 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. HBK Investments L P raised its holdings in Jazz Pharmaceuticals by 159.8% during the fourth quarter. HBK Investments L P now owns 22,600 shares of the specialty pharmaceutical company’s stock worth $3,043,000 after buying an additional 13,900 shares during the last quarter. Teachers Advisors LLC raised its holdings in Jazz Pharmaceuticals by 16.1% during the fourth quarter. Teachers Advisors LLC now owns 601,785 shares of the specialty pharmaceutical company’s stock worth $81,030,000 after buying an additional 83,426 shares during the last quarter. Ellington Management Group LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $633,000. Compagnie Lombard Odier SCmA acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $577,000. Finally, AXA raised its holdings in Jazz Pharmaceuticals by 23.2% during the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock worth $17,091,000 after buying an additional 22,007 shares during the last quarter. Hedge funds and other institutional investors own 91.21% of the company’s stock.

JAZZ has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Leerink Swann started coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $180.00 price objective on the stock. Wells Fargo reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 25th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $128.58 to $163.75 in a research note on Monday, March 19th. Finally, Bank of America increased their target price on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, February 20th. Six equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $180.78.

TRADEMARK VIOLATION WARNING: “Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals (JAZZ) Stock” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/04/16/michael-patrick-miller-sells-200-shares-of-jazz-pharmaceuticals-jazz-stock.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply